Highlights

Quest Diagnostics Completes Acquisition of Med Fusion and Clear Point in Texas, Forming National Precision Oncology Center of Excellence

July 21, 2017

FOR IMMEDIATE RELEASE

 

Quest Contacts

Wendy Bost (Media): 973-520-2800

Shawn Bevec (Investors): 973-520-2900

 

Quest Diagnostics Completes Acquisition of Med Fusion and Clear Point in Texas, Forming National Precision Oncology Center of Excellence

 

MADISON, NJ — July 18, 2017 — Quest Diagnostics (NYSE: DGX) today announced that it has completed its previously announced acquisition of the laboratory businesses Med Fusion and Clear Point. Operating from a nearly 200,000 square foot facility in Lewisville, Texas, the two businesses form the basis for the company’s first national center of excellence in precision diagnostics for oncology.

 

In connection with the transaction, Quest is now a preferred provider to several organizations that are formerly owners of one or both of these businesses. These organizations include Baylor Scott & White Health (BSWH), The US Oncology Network (The Network), Texas Oncology, and Pathologists Bio-Medical Laboratories. Specifically, Quest will provide services on a preferred basis to 12 hospitals of BSWH in North Texas and 1,400 independent, community-based physicians nationally that are affiliated with The Network, including Texas Oncology. The Network is supported by McKesson Specialty Health, a division of McKesson Corporation.

 

In addition, Quest Diagnostics will collaborate with McKesson Specialty Health, The Network and Texas Oncology to enhance and nationally scale a model created by Med Fusion that standardizes next-generation gene sequencing panels to aid therapy selection and monitoring for cancer. This approach guides the physician, within an electronic health record, to a panel individualized according to guidelines to the patient’s cancer type and stage of disease.

 

For patients with cancer, precision diagnostics, such as genomic sequencing of a tumor’s DNA, may help a physician select a therapy or clinical trial and monitor response.

 

About Quest Diagnostics

Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.  Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 43,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.  For more information, please visit www.QuestDiagnostics.com.

 

50th Anniversary: In 2017, Quest Diagnostics celebrates 50 years of life-changing results. To learn about our legacy of accomplishments and quest to improve healthcare in the future, visit www.QuestDiagnostics.com/50Years.

med fusion announces Expansion of their Solid Tumor Profiling

January 21, 2015

 

med fusion announces Expansion of their Solid Tumor Profiling
Powered by Next Generation Sequencing

Lewisville, TX (January 21, 2015) – med fusion, an integrated Molecular Center of Excellence and clinical trials service organization, today announced the release of its Solid Tumor Molecular Profiling testing services (SEQ) enhanced by Next Generation Sequencing (NGS) technology.  The introduction of NGS will further enable physicians to interrogate their patient’s tumor at the molecular level in order to develop a personalized treatment plan according to the genetic makeup of their specific tumor.

With integrated and comprehensive testing services, med fusion offers both disease-specific panels (LUNGSEQ, COLONSEQ, COLONSEQPlus) for prioritizing treatment options within Standard of Care guidelines as well as a hot spot cancer panel (50SEQ) by NGS to support treatment options for rare, refractory, or recurrent disease.  The SEQ testing results associate therapy options based upon FDA, NCCN, and ASCO guidelines in a complete and tailored report for the patient and physician.

“Genome-based testing is a more targeted and efficient strategy for physicians to identify and treat mutations that may be driving tumor growth,” commented Dr. Raul Benavides, CMO, med fusion. “Our Solid Tumor Program will continue to build upon these strategies that we have implemented for lung and colon cancers. By 2016, med fusion’s solid tumor program will expand to include molecular profiling services for melanoma, glioma, breast, and ovarian cancers.”

Aligned with their personalized and comprehensive approaches, med fusion is in network with most private and government insurance providers, and also has available flexible and reflexive molecular profiling algorithms to meet the clinical needs and cost efficiencies for physicians and patients.

“Striving to ensure every patient receives the best health care, we recognize the need to participate in the health plans of our client’s patient population,” states Jon Hart, CEO, med fusion. “As a result, med fusion is a participating provider with most national Managed Care Organizations, as well as, regional and state healthcare insurers.  Being a participating provider allows us to offer the most cost efficient testing services to our patients.

About med fusion

med fusion, an integrated molecular center of excellence and clinical trials service organization providing support to healthcare providers and biotech/pharmaceutical companies to consistently meet the needs of patients. The full service clinical laboratory includes a dedicated test development and validation team to meet the needs of clients and reference lab services such as pathology and molecular diagnostics. med fusion is committed to facilitate the realization of personalized medicine by specializing in: Oncology, Women’s Health, Urology and Infectious Disease. Headquartered in Lewisville, Texas, med fusion offers their specialized services throughout the U.S. To learn more, please visit www.medfusionservices.com.

 

 

Media Contact

 

Mary Olson

972-966-7137

molson@medfusionsvs.com

Jon L. Hart Named Chief Executive Officer of med fusion

April 7, 2014

Lewisville, Texas (April 7, 2014) ― med fusion, an integrated, advanced laboratory and clinical trials service organization, announced today the appointment of Jon L. Hart as chief executive officer, effective March 31. This appointment is the next step in the organization’s continued drive towards becoming the clear leader in providing lab and clinical trial support to healthcare providers and biotech/pharmaceutical companies through a patient-centric support model.

“Jon’s distinguished track record and more than 34 years of business leadership experience in the healthcare industry make him uniquely qualified to lead our organization,” said J. Ernest Sims, board chairman, med fusion. “His experience will help med fusion continue to ramp up its services in several areas, especially in our work with precision medicine, genetic testing and molecular diagnostics.”

As chief executive officer, Hart will lead the company’s efforts to introduce more targeted diagnostics, reduce episode of care costs and enhance system efficiencies. He will also spearhead the company’s recent collaboration with The US Oncology Network. In 2013, physicians in The Network selected med fusion as one of their preferred diagnostic laboratories. The relationship’s aim is to advance the delivery of high-quality, precision medicine – the tailoring of medical treatment to the genetic characteristics found in each patient’s tumor – and the appropriate use of molecular diagnostics. Additionally, Hart will lead med fusion and The Network’s recent pilot program on genomic testing for non small cell lung cancer (NSCLC) patients. For the pilot, physicians in The Network will test their ability to adopt a standard molecular testing approach for all NSCLC patients. The standard is a targeted biomarker panel developed by med fusion and physicians in The Network, and the pilot’s success will demonstrate The Network’s ability to lead community oncology in precision medicine.

“There are a lot of exciting initiatives happening right now at med fusion and within the healthcare industry as a whole that could benefit the delivery of high-quality patient care,” said Hart. “Precision medicine is one of them. I am pleased to announce that the company recently raised a second round of funding of 71 million dollars designed to expand our capabilities in this area. I am honored to join med fusion’s top notch team and move its precision medicine initiatives forward.”

Previously, Hart served as president and CEO of Aurora Diagnostics, a national anatomic pathology provider based in Palm Beach Gardens, FL. Prior, Hart led a business turnaround when he was in charge of Genzyme Genetics, the esoteric laboratory division of Genzyme Corporation in Cambridge, Massachusetts. Hart has held several leadership roles throughout his career for organizations such as Arthur Young & Company in Atlanta, GA. and Quest Diagnostics in Madison, NJ.

Hart graduated Magna Cum Laude from Valdosta State University in Georgia with a BBA degree in Accounting. In his new role with med fusion, Hart will be based in Lewisville, Texas.

About med fusion

Headquartered in Lewisville, Texas, med fusion is an integrated, advanced laboratory and clinical trials service organization providing support to healthcare providers and biotech/pharmaceutical companies through a patient-centric support model. The company is working to introduce more targeted diagnostics, reduce episode of care costs and enhanced system efficiencies. Based in a 130,000 square foot facility, the company’s full service clinical laboratory includes a dedicated test development and validation team to quickly meet the needs of clients and their patients. med fusion currently has over 400 well-trained employees, and a dedicated lab staff with an average of 16 years of experience.

 

For more information please visit www.medfusionservices.com.

 

Media Contact:

Mary Olson

972-966-7137

molson@medfusionsvs.com

Life Technologies, Speeding Up Turn Around Times

September 18, 2013

ClearPoint’s partner, med fusion, is one of the first to participate in the Life Technologies Premier Supply Center solution, an innovative, intelligent way for lab personnel to get the products they need, quickly and efficiently.

With the Life Technologies Premier Supply Center solution, med fusion is able to immediately access products needed, in secure on-site units which track and report inventory and transactions in real time. Users swipe-in with an access badge, take what they need and walk away. The system knows what products were removed and sends an order confirmation for each transaction.

Having such easy access to consumables such as media, enzymes, reagents, etc., enables med fusion to speed turnaround times, providing key laboratory tests to physicians faster, for better patient care.

Stocked product lists and quantities are viewable from a desktop computer or mobile device, so users know anytime, anywhere what’s available for purchase.

West Nile Virus: Make the Right Choice!

June 30, 2013

Clinical Overview

Transmission: Mosquitoes transmit the virus from birds to humans

Symptoms:
  • 80% infections are asymptomatic
  • 20% infections develop into “West Nile fever” – Mild non-specific symptoms, including fever, headache, myalgia, and occasionally a skin rash on the trunk of the body or swollen lymph nodes
  • 1% infections result in neuroinvasive disease:
  • Meningitis and/or encephalitis

Risk Factors: Advanced age, above 70 years at particularly high risk

Course of WNV infection

Viremic Phase:
  • A low-level viremia for 2 – 14 days
  • Patients are usually asymptomatic
Immune Response Phase:
  • IgM within 14 days of infection
  • IgG ~ 18-20 days
  • Patients are usually symptomatic

Cerebrospinal fluid (CSF)
  • Aids in the diagnosis of neuroinvasive disease
  • IgM in the CSF indicates acute infection with involvement of the central nervous system
  • IgM can persist for many months following initial onset of symptoms
  • CSF IgG should be positive in current or past infections, and can help confirm a positive CSF IgM. CSF IgG testing is controversial and there is not much data to support its use.
  • Serologic testing on CSF should be correlated with clinical presentation. Passive transfer of antibodies from blood or contamination with blood during lumbar puncture can lead to positive results.

Molecular Diagnosis (PCR) of WNV

PCR is less useful than serology due to following reasons:

    • Human viremia is low
    • Human viremia is transient and is rarely detectable by Day 1 of onset
    • Viremia is absent when IgM is detectable
    • Low clinical sensitivity as viral RNA is usually absent by time of symptom onset
    • Sensitivity: 57% for acute CSF; <10% serum

PCR may be useful in:

      • Early in disease, before IgM levels are detectable
      • Confirmation of suspected WNV isolates that give cross reacting Abs profile early in season
      • Immunocompromised patients with delayed or absent antibody response
      • Screening donor blood units prior to transfusion
      • Autopsy/Postmortem studies on tissues